Are there mortality risks for patients with epilepsy who use cannabis treatments as monotherapy?

Publication Title

Epilepsy Behav Case Rep

Authors

Devon M Kollmyer, Swedish Epilepsy Center, 550 17th Ave suite 540, Seattle, WA 98122, USAFollow
Kyla E Wright
Nicole M Warner, Swedish Epilepsy Center, 550 17th Ave suite 540, Seattle, WA 98122, USAFollow
Michael J Doherty, Swedish Epilepsy Center, 550 17th Ave suite 540, Seattle, WA 98122, USAFollow

Document Type

Article

Publication Date

1-1-2019

Keywords

Cannabidiol; Marijuana; Sudden unexplained death in epilepsy; Tetrahydrocannabinol; Therapy

Abstract

Mortality associated with cannabis used for treatment of epilepsy is not well documented. We discuss two fatalities in the setting of epilepsy and self-determined therapy with cannabis (SDTC). One patient had probable sudden unexpected death in epilepsy, the second death was due to seizure-associated drowning. Both directed SDTC over conventional anti-seizure medications. Where recreational cannabis is legal, decisions to use cannabis are often self-directed and independent of physician advice of cannabis risks, in part because physicians may not be aware of the risk of SDTC. Further study of morbidity and mortality of SDTC in patients with epilepsy is needed.

Clinical Institute

Neurosciences (Brain & Spine)

Specialty/Research Institute

Neurosciences